Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

[1]  David A. Williams,et al.  Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. , 2019, Blood.

[2]  Andrew J. Lee,et al.  Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. , 2019, The Journal of surgical research.

[3]  D. Torigian,et al.  Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. , 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  M. Pomper,et al.  Enhancing CAR T-cell therapy through cellular imaging and radiotherapy. , 2019, The Lancet. Oncology.

[5]  B. Shi,et al.  Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3–Targeted Chimeric Antigen Receptor–Engineered T Cells in Hepatocellular Carcinoma , 2019, The Journal of Immunology.

[6]  X. Zang,et al.  Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies , 2019, Journal of Hematology & Oncology.

[7]  B. Solomon,et al.  Supercharging adoptive T cell therapy to overcome solid tumor–induced immunosuppression , 2019, Science Translational Medicine.

[8]  S. Endres,et al.  Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy , 2019, Cells.

[9]  L. Whilding,et al.  CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid Malignancies , 2019, Cancers.

[10]  A. Shibata,et al.  Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy , 2019, Front. Oncol..

[11]  K. Curran,et al.  CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response. , 2019, Cancer cell.

[12]  Aditi Gupta,et al.  One checkpoint may hide another: inhibiting the TGFβ signaling pathway enhances immune checkpoint blockade. , 2019, Hepatobiliary surgery and nutrition.

[13]  E. Moon,et al.  CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment , 2019, Front. Immunol..

[14]  B. Heyman,et al.  Chimeric Antigen Receptor T Cell Therapy for Solid Tumors: Current Status, Obstacles and Future Strategies , 2019, Cancers.

[15]  Juliet Investigators.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma , 2019 .

[16]  Xiaojing Ma,et al.  CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions , 2018, Cancer Immunology, Immunotherapy.

[17]  Amanda M Li,et al.  Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia , 2018, Blood.

[18]  Depei Wu,et al.  Radiotherapy Priming Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden , 2018, Blood.

[19]  M. Sadelain,et al.  Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  L. Kuryk,et al.  Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model , 2018, Oncoimmunology.

[21]  H. Kaufman,et al.  Integrating oncolytic viruses in combination cancer immunotherapy , 2018, Nature Reviews Immunology.

[22]  B. Nelson,et al.  Oncolytic viruses as engineering platforms for combination immunotherapy , 2018, Nature Reviews Cancer.

[23]  Fan Zhang,et al.  Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies. , 2018, Cancer research.

[24]  C. June,et al.  Dominant-Negative TGF-β Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  W. Fisher,et al.  Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment. , 2018, Cancer discovery.

[26]  J. Delisle,et al.  TGF-β in T Cell Biology: Implications for Cancer Immunotherapy , 2018, Cancers.

[27]  Michael L. Wang,et al.  T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Spitzer,et al.  Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System , 2018, Cell reports.

[29]  S. Theocharis,et al.  The Role of Soluble CD40L Ligand in Human Carcinogenesis. , 2018, Anticancer research.

[30]  Louai Labanieh,et al.  Programming CAR-T cells to kill cancer , 2018, Nature Biomedical Engineering.

[31]  S. Russell,et al.  Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines. , 2018, Cancer cell.

[32]  C. June,et al.  Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. , 2018, JCI insight.

[33]  K. Peng,et al.  The emerging role of oncolytic virus therapy against cancer. , 2018, Chinese clinical oncology.

[34]  Zhiqiang Wu,et al.  Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy , 2018, Gene Therapy.

[35]  Pavel Sumazin,et al.  Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma , 2018, Neuro-oncology.

[36]  K. Tamada,et al.  IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor , 2018, Nature Biotechnology.

[37]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[38]  Uyen Tran,et al.  Rewiring T-cell responses to soluble factors with chimeric antigen receptors , 2018, Nature chemical biology.

[39]  J. Tolar,et al.  Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T , 2018, International journal of molecular sciences.

[40]  S. Thorne,et al.  Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines , 2018, Oncoimmunology.

[41]  R. Blasczyk,et al.  Cord blood–derived T cells allow the generation of a more naïve tumor‐reactive cytotoxic T‐cell phenotype , 2018, Transfusion.

[42]  J. Kochenderfer,et al.  Chimeric antigen receptor T-cell therapies for multiple myeloma. , 2017, Blood.

[43]  H. Abken,et al.  CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity against Advanced Solid Tumors. , 2017, Cell reports.

[44]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[45]  A. DeMichele,et al.  Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer , 2017, Cancer Immunology Research.

[46]  R. Kruse,et al.  Constitutive Signaling from an Engineered IL7 Receptor Promotes Durable Tumor Elimination by Tumor-Redirected T Cells. , 2017, Cancer discovery.

[47]  S. Gottschalk,et al.  Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  A. Hauschild,et al.  Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Act Investigators.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial , 2017 .

[50]  C. June,et al.  Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18 , 2017, Cell reports.

[51]  Zhengfei Lu,et al.  Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor–Modified T Cells Engineered to Secrete Checkpoint Inhibitors , 2017, Clinical Cancer Research.

[52]  Michael E. Lassman,et al.  Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy , 2017, Cell.

[53]  Hao Liu,et al.  CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  D. Spriggs,et al.  Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment , 2017, Scientific Reports.

[55]  R. Grossman,et al.  HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial , 2017, JAMA oncology.

[56]  Zhiqiang Wu,et al.  Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers , 2017, Protein & Cell.

[57]  Xi Zhang,et al.  Engineering CAR-T cells , 2017, Biomarker Research.

[58]  K. Wittrup,et al.  Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors , 2017, The Journal of clinical investigation.

[59]  Hao Liu,et al.  Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants , 2017, Cancer Immunology Research.

[60]  S. Gottschalk,et al.  Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors. , 2017, Cancer research.

[61]  C. June,et al.  Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy. , 2017, Cancer research.

[62]  He Huang,et al.  Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia , 2017, Experimental Hematology & Oncology.

[63]  Anping Li,et al.  Chimeric antigen receptor T cells: a novel therapy for solid tumors , 2017, Journal of Hematology & Oncology.

[64]  I. Diaconu,et al.  Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[66]  H. Heslop,et al.  Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  L. Hurton,et al.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells , 2016, Proceedings of the National Academy of Sciences.

[68]  Carl H. June,et al.  Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition , 2016, Clinical Cancer Research.

[69]  M. Brenner,et al.  Improving the safety of T-Cell therapies using an inducible caspase-9 gene. , 2016, Experimental hematology.

[70]  S. Grupp,et al.  Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. , 2016, The Journal of clinical investigation.

[71]  S. Rosenberg,et al.  Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  Xiaoxiao Wang,et al.  Correction: Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade (Cancer Cell (2016) 30(3) (500) (S1535610816300381) (10.1016/j.ccell.2016.02.004)) , 2016 .

[73]  L. Zitvogel,et al.  Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition , 2016, Oncoimmunology.

[74]  J. Bell,et al.  Oncolytic viruses—immunotherapeutics on the rise , 2016, Journal of Molecular Medicine.

[75]  Yang Feng,et al.  Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. , 2016, The Journal of clinical investigation.

[76]  Guoliang Ding,et al.  Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches , 2016, Science China Life Sciences.

[77]  Chun Jimmie Ye,et al.  CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells , 2016, Scientific Reports.

[78]  G. Freeman,et al.  Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model , 2016, Oncotarget.

[79]  P. Allavena,et al.  Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient , 2016, Journal of Immunotherapy for Cancer.

[80]  J. Maher,et al.  Role of the colony-stimulating factor (CSF)/CSF-1 receptor axis in cancer. , 2016, Biochemical Society transactions.

[81]  Y. Chen,et al.  T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells , 2016, Cancer Immunology Research.

[82]  Xiaoxiao Wang,et al.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. , 2016, Cancer cell.

[83]  C. Leslie,et al.  Cancer Immunosurveillance by Tissue-Resident Innate Lymphoid Cells and Innate-like T Cells , 2016, Cell.

[84]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[85]  S. Turley,et al.  Immunological hallmarks of stromal cells in the tumour microenvironment , 2015, Nature Reviews Immunology.

[86]  P. Darcy,et al.  Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. , 2015, Molecular immunology.

[87]  J. Bramson,et al.  Chimeric antigen receptor–engineered T cells as oncolytic virus carriers , 2015, Molecular therapy oncolytics.

[88]  David J Mooney,et al.  Injectable cryogel-based whole-cell cancer vaccines , 2015, Nature Communications.

[89]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[90]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[91]  I. Pastan,et al.  Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1&agr;-secreting Glioblastoma , 2015, Journal of immunotherapy.

[92]  S. Katz,et al.  Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor–Modified T-cell Therapy for CEA+ Liver Metastases , 2015, Clinical Cancer Research.

[93]  K. Curran,et al.  Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[94]  D. Spriggs,et al.  A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer , 2015, Journal of Translational Medicine.

[95]  J. Yewdell,et al.  CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells. , 2015, Immunity.

[96]  M. Carroll,et al.  CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia , 2015, Leukemia.

[97]  Sadik H. Kassim,et al.  Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  D. Spriggs,et al.  IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo , 2015, Oncoimmunology.

[99]  P. Darcy,et al.  Trafficking of T cells into tumors. , 2014, Cancer research.

[100]  Youngjin Choi,et al.  Injectable, spontaneously assembling inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy , 2014, Nature Biotechnology.

[101]  C. von Kalle,et al.  CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[102]  S. Giralt,et al.  IL-12-secreting CD19-targeted cord blood-derived T cells for the immunotherapy of B-cell acute lymphoblastic leukemia , 2014, Leukemia.

[103]  C. Breitbach,et al.  Going viral with cancer immunotherapy , 2014, Nature Reviews Cancer.

[104]  P. Hauser,et al.  Development and Characterization of a Preclinical Model of Breast Cancer Lung Micrometastatic to Macrometastatic Progression , 2014, PloS one.

[105]  G. Coukos,et al.  Tumor Endothelium FasL Establishes a Selective Immune Barrier Promoting Tolerance in Tumors , 2014, Nature Medicine.

[106]  G. Coukos,et al.  T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. , 2014, Cancer discovery.

[107]  S. Gerber,et al.  Optogenetic control of chemokine receptor signal and T-cell migration , 2014, Proceedings of the National Academy of Sciences.

[108]  W. Burns,et al.  A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. , 2014, Human gene therapy.

[109]  Dean Sheppard,et al.  TGF-β activation and function in immunity. , 2014, Annual review of immunology.

[110]  M. Speicher,et al.  Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients , 2014, Science Translational Medicine.

[111]  T. Hermiston,et al.  Armed Therapeutic Viruses – A Disruptive Therapy on the Horizon of Cancer Immunotherapy , 2014, Front. Immunol..

[112]  H. Abken,et al.  Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma , 2014, Immunological reviews.

[113]  D. Torigian,et al.  Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies , 2013, Cancer Immunology Research.

[114]  J. Spicer,et al.  Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. , 2013, Human gene therapy. Clinical development.

[115]  P. Darcy,et al.  Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment , 2013, Oncoimmunology.

[116]  S. Ghaem-Maghami,et al.  Synergistic Chemoimmunotherapy of Epithelial Ovarian Cancer Using ErbB-Retargeted T Cells Combined with Carboplatin , 2013, The Journal of Immunology.

[117]  M. Smyth,et al.  Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells , 2013, Clinical Cancer Research.

[118]  Andreas Thiel,et al.  CD40L expression permits CD8+ T cells to execute immunologic helper functions. , 2013, Blood.

[119]  Matthew L Baker,et al.  TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy , 2013, Molecular therapy. Nucleic acids.

[120]  M. Hidalgo,et al.  Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer. , 2013 .

[121]  O. Woo,et al.  Tumor-infiltrating Lymphocytes, Tumor Characteristics, and Recurrence in Patients With Early Breast Cancer , 2013, American journal of clinical oncology.

[122]  M. Glennie,et al.  Agonistic CD40 Antibodies and Cancer Therapy , 2013, Clinical Cancer Research.

[123]  H. Inoue,et al.  Co-Introduced Functional CCR2 Potentiates In Vivo Anti-Lung Cancer Functionality Mediated by T Cells Double Gene-Modified to Express WT1-Specific T-Cell Receptor , 2013, PloS one.

[124]  A. Tolcher,et al.  Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors , 2013, Oncoimmunology.

[125]  S. Rosenberg,et al.  Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy , 2012, Gene Therapy.

[126]  S. Forman,et al.  Tumor PD-L1 co-stimulates primary human CD8(+) cytotoxic T cells modified to express a PD1:CD28 chimeric receptor. , 2012, Molecular immunology.

[127]  S. Russell,et al.  ONCOLYTIC VIROTHERAPY , 2012, Nature Biotechnology.

[128]  T. Kipps,et al.  Gene immunotherapy of chronic lymphocytic leukemia: a phase I study of intranodally injected adenovirus expressing a chimeric CD154 molecule. , 2012, Cancer research.

[129]  M. Sadelain,et al.  Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. , 2012, Blood.

[130]  Matthew J. Craig,et al.  IL‐4 induces proliferation in prostate cancer PC3 cells under nutrient‐depletion stress through the activation of the JNK‐pathway and survivin up‐regulation , 2012, Journal of cellular biochemistry.

[131]  S. Rosenberg,et al.  Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice , 2012, Clinical Cancer Research.

[132]  A. Ashkar,et al.  Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity , 2011, Cancer Gene Therapy.

[133]  R. Vile,et al.  GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution , 2011, Gene Therapy.

[134]  A. Hemminki,et al.  Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 , 2011, Gene Therapy.

[135]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[136]  Adrian P Gee,et al.  Inducible apoptosis as a safety switch for adoptive cell therapy. , 2011, The New England journal of medicine.

[137]  R. Bhadra,et al.  Cutting Edge: CD40–CD40 Ligand Pathway Plays a Critical CD8-Intrinsic and -Extrinsic Role during Rescue of Exhausted CD8 T Cells , 2011, The Journal of Immunology.

[138]  H. Abken,et al.  IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. , 2011, Cancer research.

[139]  Jing Sun,et al.  Expression of a Functional CCR2 Receptor Enhances Tumor Localization and Tumor Eradication by Retargeted Human T cells Expressing a Mesothelin-Specific Chimeric Antibody Receptor , 2011, Clinical Cancer Research.

[140]  S. Rosenberg,et al.  Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[141]  Z. Guo,et al.  Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[142]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[143]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[144]  S. Carotta,et al.  The Interactions of Multiple Cytokines Control NK Cell Maturation , 2010, The Journal of Immunology.

[145]  C. Rooney,et al.  Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b , 2010, Journal of immunotherapy.

[146]  C. Liu,et al.  Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses , 2010, Clinical Cancer Research.

[147]  T. Kipps,et al.  A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154 , 2010, Leukemia.

[148]  R. Alemany,et al.  Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[149]  J. Spicer,et al.  Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4* , 2010, The Journal of Biological Chemistry.

[150]  M. Sadelain,et al.  IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. , 2010, Blood.

[151]  H. Heslop,et al.  Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety , 2010, Leukemia.

[152]  L. Young,et al.  CD40 Ligand-Induced Carcinoma Cell Death: A Balance between Activation of TNFR-Associated Factor (TRAF) 3-Dependent Death Signals and Suppression of TRAF6-Dependent Survival Signals , 2009, The Journal of Immunology.

[153]  J. D. Vos,et al.  Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH–B cell axis , 2009, Leukemia.

[154]  H. Heslop,et al.  T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. , 2009, Blood.

[155]  E. Holland,et al.  Modeling Adult Gliomas Using RCAS/t-va Technology. , 2009, Translational oncology.

[156]  yang-xin fu,et al.  Immunoregulation by tumor necrosis factor superfamily member LIGHT , 2009, Immunological reviews.

[157]  M. Tretiakova,et al.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. , 2009, Cancer research.

[158]  J. Cody,et al.  Armed replicating adenoviruses for cancer virotherapy , 2009, Cancer Gene Therapy.

[159]  A. Melcher,et al.  Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors , 2008, Gene Therapy.

[160]  yang-xin fu,et al.  Targeting tumors with LIGHT to generate metastasis-clearing immunity. , 2008, Cytokine & growth factor reviews.

[161]  J. Kirkwood,et al.  A Dose-Escalation Study of Recombinant Human Interleukin-18 Using Two Different Schedules of Administration in Patients with Cancer , 2008, Clinical Cancer Research.

[162]  E. Tartour,et al.  The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. , 2008, Cancer research.

[163]  M. Todaro,et al.  Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4 , 2008, Cell Death and Differentiation.

[164]  G. Freeman,et al.  PD-1 and its ligands in tolerance and immunity. , 2008, Annual review of immunology.

[165]  F. Farzaneh,et al.  Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation. , 2008, Molecular immunology.

[166]  Y. Wan,et al.  Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy , 2007, Clinical Cancer Research.

[167]  Youjin Lee,et al.  Targeting the Primary Tumor to Generate CTL for the Effective Eradication of Spontaneous Metastases1 , 2007, The Journal of Immunology.

[168]  S. Rosenberg,et al.  Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? , 2006, Nature Clinical Practice Oncology.

[169]  C. Blank,et al.  Immune resistance orchestrated by the tumor microenvironment , 2006, Immunological reviews.

[170]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[171]  M. Cooke,et al.  Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors , 2006, Nature Medicine.

[172]  S. Rosenberg,et al.  Primary Human T Lymphocytes Engineered with a Codon-Optimized IL-15 Gene Resist Cytokine Withdrawal-Induced Apoptosis and Persist Long-Term in the Absence of Exogenous Cytokine1 , 2005, The Journal of Immunology.

[173]  Atique U. Ahmed,et al.  Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells , 2005, Nature Medicine.

[174]  H. Heslop,et al.  An inducible caspase 9 safety switch for T-cell therapy. , 2005, Blood.

[175]  J. Xiang,et al.  Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma , 2005, Cancer Gene Therapy.

[176]  B. Ameredes,et al.  Tolerance induced by inhaled antigen involves CD4+ T cells expressing membrane-bound TGF-β and FOXP3 , 2004 .

[177]  T. Waldmann,et al.  IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[178]  H. Heslop,et al.  A strategy for treatment of Epstein–Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells , 2004, Cancer Gene Therapy.

[179]  Youjin Lee,et al.  Priming of naive T cells inside tumors leads to eradication of established tumors , 2004, Nature Immunology.

[180]  J. Massagué,et al.  Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer , 2003, Nature Reviews Cancer.

[181]  F. Marincola,et al.  Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. , 2002, Human gene therapy.

[182]  B. Rocha,et al.  A Role for CD40 Expression on CD8+ T Cells in the Generation of CD8+ T Cell Memory , 2002, Science.

[183]  J. Houghton,et al.  Modulation of the Fas Signaling Pathway by IFN-γ in Therapy of Colon Cancer: Phase I Trial and Correlative Studies of IFN-γ, 5-Fluorouracil, and Leucovorin , 2002 .

[184]  G. Trinchieri,et al.  Interleukin-12 in anti-tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[185]  J. Xiang,et al.  Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells. , 2002, Cancer biotherapy & radiopharmaceuticals.

[186]  M. Halterman,et al.  A novel approach to cancer therapy using an oncolytic herpes virus to package amplicons containing cytokine genes. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[187]  T. Waldmann,et al.  Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[188]  A. Ramsay,et al.  Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox , 2001, Journal of Virology.

[189]  L. Rassenti,et al.  CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. , 2000, Blood.

[190]  D. Olive,et al.  Reciprocal Expression of the TNF Family Receptor Herpes Virus Entry Mediator and Its Ligand LIGHT on Activated T Cells: LIGHT Down-Regulates Its Own Receptor1 , 2000, The Journal of Immunology.

[191]  T. Waldmann,et al.  IL-2-induced activation-induced cell death is inhibited in IL-15 transgenic mice. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[192]  S. Ostrand-Rosenberg,et al.  Mouse 4T1 Breast Tumor Model , 2000, Current protocols in immunology.

[193]  Lieping Chen,et al.  LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response1 , 2000, The Journal of Immunology.

[194]  T. Kipps,et al.  Gene transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. , 1998, The Journal of clinical investigation.

[195]  J. Leonard,et al.  Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production , 1997 .

[196]  F. Pixley,et al.  Biology and action of colony‐stimulating factor‐1 , 1997, Molecular reproduction and development.

[197]  N. Boiani,et al.  Functional CD40 ligand expression on T lymphocytes in the absence of T cell receptor engagement: involvement in interleukin‐2‐induced interleukin‐12 and interferon‐γ production , 1996, European journal of immunology.

[198]  J. Pollard,et al.  The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[199]  B. Kacinski,et al.  CSF-1 and its receptor in ovarian, endometrial and breast cancer. , 1995, Annals of medicine.

[200]  M. de Carli,et al.  IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. , 1992, Journal of immunology.

[201]  E. Clark,et al.  Molecular and biological characterization of a murine ligand for CD40 , 1992, Nature.

[202]  D. Maloney,et al.  High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. , 2019, Blood.

[203]  J. Kochenderfer,et al.  Chimeric antigen receptor T-cell therapies for lymphoma , 2018, Nature Reviews Clinical Oncology.

[204]  M. Weller,et al.  NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. , 2018, Cancer research.

[205]  L. Recht,et al.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. , 2017, The Lancet. Oncology.

[206]  S. Ferrini,et al.  Dual Roles of IL-15 in Cancer Biology , 2016 .

[207]  R. Ortíz-López,et al.  Oncolytic virotherapy. , 2008, Annals of hepatology.

[208]  Christopher B Wilson,et al.  Regulation of interferon-gamma during innate and adaptive immune responses. , 2007, Advances in immunology.

[209]  C. Ware.  Network communications: lymphotoxins, LIGHT, and TNF. , 2005, Annual review of immunology.

[210]  P. Libby,et al.  The CD40/CD154 receptor/ligand dyadRID="†"ID="†" Review , 2001, Cellular and Molecular Life Sciences CMLS.

[211]  D. Chaplin,et al.  Development and maturation of secondary lymphoid tissues. , 1999, Annual review of immunology.

[212]  C. Ware,et al.  LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. , 1998, Immunity.